Hemoperfusion with an immobilized polymyxin B fiber column decreases macrophage and monocyte activity

Therapeutic Apheresis and Dialysis

Volumn 13, Issue 6, 2009, Pages 515-519

  Kushi, Hidehiko ^a,b   Miki, Takahiro ^b   Sakagami, Yuichiro ^c   Sato, Jun ^a,b   Saito, Takeshi ^a,b   Tanjoh, Katsuhisa ^a  

^a NIHON UNIVERSITY   (Japan)

^b SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

^c CSL Behring KK   (Japan)

Author keywords

Immobilized polymyxin B fiber column; Macrophage; Monocyte; Neopterin; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

ANTIBIOTIC AGENT; CATECHOLAMINE; NAFAMSTAT MESILATE; NEOPTERIN; POLYMYXIN B;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CELL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; FEMALE; HEMOPERFUSION; HUMAN; IMMOBILIZED POLYMYXIN B FIBER COLUMN; IMMUNOMODULATION; INFECTION; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MEAN ARTERIAL PRESSURE; MONOCYTE; PRIORITY JOURNAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THERAPY EFFECT; THERMODILUTION;

ADULT; AGED; BLOOD PRESSURE; FEMALE; HEMOPERFUSION; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; NEOPTERIN; POLYMYXIN B; PROSPECTIVE STUDIES; SEPSIS; THERMODILUTION;

EID: 71949127552     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00778.x     Document Type: Article

References (25)

1. O'Reilly M, Newcomb DE, Remick D. Endotoxin, sepsis, and the primrose path. Shock 1999 12 : 411 420.
2. Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s. J Am Med Ass 1994 271 : 226 233.
3. Madoff R, Sharpe S, Cerra FB. Prolonged surgical intensive care. Arch Surg 1985 120 : 698 702.
4. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure for the use of innovative therapies in sepsis. Chest 1992 101 : 1644 1655.
5. Ziegler EJ, Fisher CJ, Sprung CL et al. Treatment of Gram-negative bacteremia and shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991 324 : 429 436.
6. Quezado ZMN, Banks SM, Natanson C. New strategies for combating sepsis: the magic bullets missed the mark. but the search continues. Trends Biotechnol 1995 13 : 56 63.
7. Jaber BL, Barrett TW, Neto MC, Sundaram S, King AJ, Pereira BJG. Removal of cytokine inducing substances by polymyxin-B immobilized polystyrene- derivative fibers during in vitro hemoperfusion of 10% human plasma containing Staphylococcus aureus challenge. ASAIO J 1998 44 : 48 53.
8. Nemoto H, Nakamoto H, Okada H et al. Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 2001 19 : 361 369.
9. Uriu K, Osajima A, Kamochi M, Watanabe H, Aibara K, Kaizu K. The severity of hyperdynamic circulation may predict the effects of direct hemoperfusion with the adsorbent column using polymyxin B-immobilized fiber in patients with Gram-negative septic shock. The Apher Dial 2001 5 : 25 30.
10. Vincent JL, Laterre PF, Cohen J et al. A pilot controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005 23 : 400 405.
11. Kushi H, Miki T, Okamaoto K, Nakahara J, Saito T, Tanjoh K. Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 2005 9.
12. Kushi H, Nakahara J, Miki T, Okamoto K, Saito T, Tanjoh K. Hemoperfusion with an immobilized polymyxin B fiber column inhibits activation of vascular endothelial cells. Ther Apher Dial 2005 9 : 303 307.
13. Kushi H, Miki T, Nakahara J et al. Hemoperfusion with an immobilized polymyxin B fiber column reduces circulating intrleukin-8 concentrations. Ther Apher Dial 2006 10 : 425 429. (Pubitemid 44652203)
14. Kushi H, Miki T, Nakahara J, Okamoto K, Saito T, Tanjoh K. Hemoperfusion with an immobilized polymyxin B column reduces the blood level of neutrophil elastase. Blood Purif 2006 24 : 212 217. (Pubitemid 43259176)
15. Kushi H, Miki T, Nakahara J et al. Hemoperfusion with an immobilized polymyxin B fiber improves tissue oxygen metabolism. Ther Apher Dial 2006 10 : 430 435.
16. Hoshiai K, Hattan N, Fukuyama N et al. Increased plasma tetrahydrobiopterin in septic shock in a possible therapeutic target. Pathophysiology 2001 7 : 275 281.
17. Kushi H, Miki Sakagami Y, Saito T, Tanjoh K. Criteria for hemoperfusion with an immobilized polymyxin B fiber column based oxygen metabolism. Ther Apher Dial 2008 12 : 292 297.
18. Knaus WA, Draper EA, Wanger DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985 13 : 818 820.
19. Fuchs D, Weiss G, Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol 1993 101 : 1 6.
20. Vrecko K, Staedtler P, Mischak I, Maresch L, Reibnegger G. Periodontitis and concentrations of the cellular immune activation marker neopterin in salvia and urine. Clin Chim Acta 1997 268 : 31 40.
21. Müller MM, Curtius HC, Herold M, Huber CH. Neopterin in clinical practice. Clin Chim Acta 1991 201 : 1 16.
22. Radunovic N, Kuczynski E, Rebarber A, Nastic D, Lockwood CJ. Neopterin concentrations in fetal and maternal blood: a maker of cell-mediated immune activation. Am J Obstet Gynecol 1999 181 : 170 173.
23. Huber C, Batchelor JR, Fuchs D. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984 160 : 310 316.
24. Pascual C, Karzai W, Meier-Hellmann A et al. Total plasma antioxidant capacity is not always decreased in sepsis. Crit Care Med 1998 26 : 705 709.
25. Nakamura T, Ebihara I, Shimada N et al. Effects of hemoperfusion with polymyxin B-immobilized fiber on serum neopterin and soluble interleukin-2 receptor concentrations in patients with septic shock. J Infect 1998 37 : 241 247. (Pubitemid 29017270)